Display Settings:

Format

Send to:

Choose Destination
Curr Opin Gastroenterol. 2012 May;28(3):188-92. doi: 10.1097/MOG.0b013e3283528e1e.

Hepatitis C therapy update.

Author information

  • 1Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390–8887, USA.

Abstract

PURPOSE OF REVIEW:

We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field.

RECENT FINDINGS:

Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy.

SUMMARY:

Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

PMID:
22476156
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk